Investors

Recent Investment and Other Funding

Jan 2010
Signum Biosciences has been awarded a $270K grant from the Alzheimer's Drug Discovery Foundation to investigate, "PP2A: A novel therapeutic target for Alzheimer's Disease".

Sept 2009
Signum Biosciences has been awarded a $1.6 million SBIR Phase II grant by the NIAID to continue the development of its topical STM anti-inflammatory technology for the treatment of skin disease. Read the press release

Signum Biosciences recieved a $2 million equity investment.

Feb 2009
Signum Biosciences and Rohto conclude licensing agreement for first Arazine^™ product. It will be introduced in Japan Q2 2010.

Nov 2008
Signum Biosciences secures a credit facility with a maximum draw amount of $5 million.

Oct 2008
Signum Biosciences closes a funding round raising $2.5 million.

Aug 2008
Dr. Jose Fernandez, PhD, awarded NJCST fellowship ($75K) to support his work at Signum Biosciences

May 2008

Rohto’s President and CEO, Kunio Yamada has accepted a seat on Signum’s board and has made a significant investment in our company.

Sep 2007
Dr. Eduardo Perez, PhD, awarded 2nd year NJCST fellowship ($85K) to continue his research efforts with Signum

Jul 2007
Signum Biosciences closes a $2.5 million private placement.

Apr 2007
Signum Biosciences closes a $1 million long term loan from the New Jersey Economic Development Authority.

Jan 2007
Signum completes a private placement for $1.8 million.

Sep 2006
Dr. Eduardo Perez, PhD, and Dr. David Fela, PhD, are awarded NJCST fellowships ($160K) to support their work at Signum Biosciences.

Jun 2006
Signum Biosciences receives a $500K development grant from the NJCST.

To obtain information please contact: invest@signumbio.com